NCT01890798View on ClinicalTrials.gov

Drisapersen Duchenne Muscular Dystrophy (DMD) Treatment Protocol

PHASE3WithdrawnINTERVENTIONAL

Timeline

Start Date

January 31, 2014

Primary Completion Date

January 31, 2014

Study Completion Date

July 31, 2015

Conditions

Muscular Dystrophies

Interventions

DRUG

Drisapersen

Drisapersen will be supplied as 3 millilitre (mL) vials containing 1mL sterile solution for subcutaneous injection. The strength of drisapersen solution will be 200 mg/mL.